Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort studyAndrea Chiricozzi, Clara De Simone, Elena Ippoliti et al.|Expert Opinion on Biological Therapy|2023Cited by 10
<scp>KRAS</scp> mutation identified in a patient with melorheostosis and extended lymphangiomatosis treated with sirolimus and trametinibClara Lacasta‐Plasín, Minia Campos‐Domínguez, Víctor Martínez‐Glez et al.|Clinical Genetics|2021Cited by 8
Author response for "KRAS mutation identified in a patient with melorheostosis and extended lymphangiomatosis treated with sirolimus and trametinib"Clara Lacasta‐Plasín, Minia Campos‐Domínguez, Víctor Martínez‐Glez et al.|Unknown|2021Cited by 0
Author response for "KRAS mutation identified in a patient with melorheostosis and extended lymphangiomatosis treated with sirolimus and trametinib"Clara Lacasta‐Plasín, Minia Campos‐Domínguez, Víctor Martínez‐Glez et al.|Unknown|2021Cited by 0
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort studyAndrea Chiricozzi, Ketty Peris, Silvia Mariel Ferrucci et al.|Figshare|2023Cited by 0